The clinically active ATR inhibitor, VE-822, also potentiated etoposide and the topoisomerase I poison, SN-38, in a panel of lung cancer cells, though not to the extent seen with gemcitabine and cisplatin [82]. This evidence concerns the gene ATR and lung carcinoma.